Here we provide evidence that rfhSP-D treatment increased the release of HMGB1 from the nucleus and a significant translocation of CRT to the cell surface, suggesting a novel mechanism through which rfhSP-D enhances immunogenicity of the tumour via ICD induction. This evidence concerns the gene HMGB1 and neoplasm.